







































fully	 automated	hematoxylin	&	eosin-stain	 image	analysis	 algorithm	and	 spatial	 statistics	 for	
1,178	 postmenopausal	 patients	 with	 ER+	 breast	 cancer	 treated	 with	 5	 years’	 tamoxifen	 or	




Scores	 of	 immune	 cell	 abundance	 were	 not	 associated	 with	 recurrence-free	 survival.	 In	
contrast,	 high	 immune	 spatial	 scores	 indicating	 increased	 cell	 spatial	 clustering	 were	
associated	 with	 poor	 10-year,	 early	 (0-5	 year)	 and	 late	 (5-10	 year)	 recurrence-free	 survival	
(Immune	Hotspot	LR-χ2	=	14.06,	P	<	0.001	for	0-10	year;	LR-χ2	=	6.24,	P	=	0.01	for	0-5	year;	LR-χ2	
=	7.89,	P	=	0.005	for	5-10	year).	The	prognostic	value	of	spatial	scores	for	late	recurrence	was	
similar	 to	 that	 of	 IHC4	 and	 RS	 in	 both	 populations,	 but	 was	 not	 as	 strong	 as	 other	 tests	 in	
comparison	for	recurrence	across	10	years.		
Conclusions	
These	 results	 provide	 a	 missing	 link	 between	 tumor	 immunity	 and	 disease	 outcome	 in	 ER+	
disease	by	examining	 tumor	 spatial	 architecture.	The	association	between	spatial	 scores	and	
late	recurrence	suggests	a	lasting	memory	of	pro-tumor	immunity	that	may	impact	on	disease	
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the	most	 common	cancer	 in	women.	At	diagnosis,	 the	majority	of	ER+	patients	have	a	good	
prognosis	if	treated	with	endocrine	therapy.	However,	a	subset	of	patients	is	at	risk	for	disease	
recurrence	and	death,	particularly	after	5	years	of	adjuvant	endocrine	therapy.	Differentiating	
these	 patients	 from	 low-risk	 patients	 who	 can	 safely	 avoid	 chemotherapy	 is	 a	 priority	 for	
breast	 cancer	 management	 (1).	 Currently	 available	 prognostic	 tests	 to	 predict	 risk	 in	
endocrine-treated	 patients	 include	 the	 widely	 used	 Oncotype	 DX	 21-gene	 recurrence	 score	
(RS)	 (2),	 the	PAM50	risk	of	recurrence	(ROR)	score	(3),	and	the	 immunohistochemistry-based	
IHC4	 test	 that	 is	 combined	 with	 the	 clinical	 treatment	 score	 (CTS)	 to	 integrate	
clinicopathological	 parameters	 (4).	 In	 particular,	 the	 amount	 of	 prognostic	 information	
provided	for	long-term	(0-10	years)	and	late	(beyond	five	years)	recurrence	varies	across	these	
tests	(5,	6).		
Immune	 infiltration	 is	 not	 explicitly	 accounted	 for	 in	 any	 of	 the	 above	 tests.	
Increasing	 evidence	 supports	 the	 role	 of	 tumor-infiltrating	 lymphocytes	 (TILs)	 in	 influencing	
disease	progression	and	 treatment	 response	 in	breast	 cancer	 (7-10). Characterization	of	 the	
nature	 of	 immune	 responses	 is	 key	 to	 understanding	 tumor	 immunity	 and	 empowering	
immunotherapy.		However,	the	majority	of	reports	focus	on	ER-	and	Human	Epidermal	growth	
factor	receptor	2-positive	(HER2+)	breast	cancers,	where	extensive	immune	infiltration	is	more	





We	 have	 developed	 quantitative	 and	 reproducible	 approaches	 to	 score	 lymphocytic	
infiltration	 (LI)	 in	 breast	 cancer,	 based	 on	 fully	 automated	 image	 analysis	 of	 routinely	
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generated	hematoxylin	&	eosin	(H&E)-stained	histology	sections.	Quantitative	immune	scores	
of	 overall	 LI	 in	 tumors,	 as	well	 as	 intra-tumor	 lymphocyte	 ratio	 (ITLR),	were	 associated	with	
good	survival	 in	ER-	and	ER-/HER2-	breast	cancer	 (17,	18).	 In	addition,	our	automated	 image	
analysis	 scheme	 enables	 the	 study	 of	 complex	 spatial	 patterns	 of	 TILs	 (19).	 The	 spatial	
interactions	 among	 TILs	 and	 cancer	 cells	 generate	 complex	 ecological	 dynamics	 that	 can	





their	 prognostic	 value	with	 established	 prognostic	 tests	 including	 RS,	 ROR,	 IHC4	 and	 CTS;	 3)	






Classical	 clinicopathologic	 factors	 (age,	 nodal	 status,	 tumor	 size,	 grade,	 randomized	
treatment)	were	collected	from	patients	with	ER+	primary	breast	cancer	in	the	ATAC	trial	who	
were	 randomly	 assigned	 to	 either	 anastrozole	 or	 tamoxifen	 (23)	 (Supplementary	 Table	 1).	
1,178	eligible	patients	who	did	not	receive	chemotherapy	and	from	whom	H&E-stained	slides	
from	 formalin-fixed,	 paraffin-embedded	 tissues	 were	 available	 were	 included	 (Figure	 1).	 Of	
these,	 963	 patients	 were	 scored	 with	 prognostic	 scores	 including	 IHC4,	 RS,	 ROR46	 and	 CTS	
(Table	 1).	 1,037	 tumors	 were	 HER2-,	 909	 of	 which	 were	 scored	 with	 prognostic	 scores.	 A	
subset	 of	 91	 TransATAC	 samples	 were	 randomly	 selected	 and	 scored	 on	 H&E	 sections	










stromal	 cells	 to	 differentiate	 them	 in	H&E	 histological	 tissue	 sections.	 Cancer	 cell	 nuclei	 are	
generally	 large	 in	 size	 and	 demonstrate	 greater	 variability	 in	 appearance	 as	 compared	 to	
lymphocyte	 and	 stromal	 cell	 nuclei;	 lymphocyte	 nuclei	 are	 typically	 small,	 round	 and	
homogeneously	 basophilic,	 and	 nuclei	 of	 stromal	 cells	 including	 fibroblasts	 and	 endothelial	
cells	are	more	elongated.	The	pipeline	consisted	of	four	stages:	(1)	unsupervised	segmentation	
of	 the	 nuclei;	 (2)	 supervised	 classification	 of	 individual	 cell	 nuclei	 into	 cancer,	 lymphocyte,	
other	cell	nuclei,	and	artefacts;	(3)	kernel	smoothing	to	correct	local	sporadic	errors;	and	(4)	a	
hierarchical	multi-resolution	model	 fitting	 to	 identify	 cancer	 cell	 clusters	 to	 further	 improve	
classification	accuracy.	The	classifier	was	previously	validated	in	METABRIC	to	have	an	overall	
accuracy	of	 90.1%	and	a	high	 correlation	 between	 image	 analysis	 and	pathological	 scores	 in	
the	entire	cohort	(17).	
To	evaluate	the	accuracy	of	our	image	analysis	pipeline	for	TransATAC,	a	test	set	of	627	
cells	 randomly	 sampled	 from	 3	 images	 were	 annotated	 by	 a	 pathologist	 (DNR)	 blinded	 to	
image	analysis	results	(Supplementary	Figure	1A).	Accuracy	for	identifying	the	three	cell	types	
was:	cancer	cell	93.8%,	lymphocyte	87.9%	and	stromal	cell	84.2%	(Supplementary	Figure	1B).	
The	 balanced	 accuracy	 as	 the	 average	 for	 sensitivity	 and	 specificity	 for	 the	 three	 cell	 types	
were	0.864	for	cancer,	0.839	for	lymphocyte	and	0.876	for	stromal	cell	(Supplementary	Figure	
1C).	 On	 average	 217,101	 cancer	 cells	 (±178677.5),	 25,956	 lymphocytes	 (±35365.21)	 and	
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the	 fraction	 of	 lymphocytes	 in	 all	 cells	 in	 the	 tumor	 section,	 Intra-Tumor	 Lymphocyte	 Ratio	
(ITLR),	 Adjacent-to-Tumor	 Lymphocyte	 Ratio	 (ATLR)	 and	 Distal-To-Tumor	 Lymphocyte	 Ratio	
(DTLR)	which	are	defined	as	 the	number	of	 specific	 types	of	 lymphocytes	normalized	by	 the	
number	 of	 cancer	 cells	 (17,	 18).	 Intra-Tumor	 Lymphocytes	 (ITLs),	 Adjacent-to-Tumor	





was	 carried	 out	 to	 identify	 tumor	 regions	 with	 statistically	 significant	 spatial	 clustering	 of	
immune	 cells,	 i.e.,	 immune	 hotspots. This	 means	 that,	 the	 frequency	 of	 immune	 cells	
appearing	 at	 these	 locations	 is	 greater	 than	expected	by	 chance	given	 the	distribution	of	 all	
cells	in	the	entire	tumor	section	and	that,	importantly,	the	difference	between	the	actual	and	
expected	 value	 is	 statistically	 significant.	 A	 p-value	 was	 computed	 for	 each	 spatial	 region,	
which	 can	 be	 used	 to	 determine	 statistical	 significance	 using	 a	 significance	 level	 of	 0.05.	
Previously,	tumors	with	a	high	amount	of	regions	that	are	both	immune	hotspots	and	cancer	
hotspots	 (immune-cancer	 hotspots)	 were	 found	 to	 have	 good	 prognosis	 in	 ER-	 cancer	 (13).	
Here	 for	 comparison	 in	 ER+	breast	 cancer,	 Cancer	Hotspot	 and	 Immune	Hotspot	 scores	 that	
examine	only	one	type	of	cell	at	a	time	were	also	included.		
For	 validation	 of	 the	 inter-correlations	 among	 immune	 scores,	 H&E-stained,	 whole-






Our	 primary	 objective	 was	 to	 assess	 whether	 immune	 scores	 had	 statistically	
significant	 prognostic	 information	 for	 predicting	 10-year	 recurrence	 in	 postmenopausal	
women	 with	 breast	 cancer	 given	 either	 tamoxifen	 or	 anastrozole	 monotherapy	 but	 not	
chemotherapy.	 Secondary	 analyses	 included	 determining	 the	 prognostic	 ability	 of	 immune	
scores	 in	predicting	early	 (0-5	year)	and	 late	 recurrences	 (5-10	year),	 in	patients	divided	 into	
subgroups	 by	 HER2	 status,	 and	 the	 additional	 prognostic	 information	 provided	 by	 tests	 in	
multivariable	 comparisons	 including	age	 (<65,	 ≥65	 years),	 nodal	 status	 (0,1-3,4+),	 tumor	 size	
(≤1cm,	 >1	 to	 ≤2cm,	 >2to	 ≤3cm,	 >3	 cm),	 centrally	 read	 grade	 (poor,	 intermediate,	 well	
differentiated),	and	randomized	treatment	(anastrozole	v	tamoxifen).	Hazard	Ratios	are	for	a	
change	 in	 1	 SD	 in	 the	 overall	 dataset	 to	 compare	 the	 effect	 size	 between	different	 immune	
scores.	 The	 contribution	 of	 each	 of	 the	 variables	was	 evaluated	 by	 the	 change	 in	 likelihood	
ratio	 χ2	 (LR-χ2;	 1	 df,	 significance	 level	 χ2=3.84)	 in	 three	 ways:	 by	 univariate	 analyses,	 as	 an	
addition	to	a	model	containing	only	the	clinical	variables,	and	as	a	difference	in	LR-χ2	when	the	
variable	was	added	to	 the	 IHC4	score.	Sample	splitting	was	used	 in	which	 the	 immune	score	
was	 dichotomized	 by	 using	 half	 the	 data	 as	 the	 training	 set,	 and	 then	 the	 cut-off	 points	 for	
each	score	were	evaluated	in	the	remaining	half	of	the	data	as	the	validation	set.	Since	the	use	
of	optimizing	cut-offs	may	lead	to	overestimation	of	prognostic	power,	dichotomized	variables	










Four	 immune	 abundance	 scores	 (overall	 Lymphocytic	 Infiltration	 LI,	 Intra-Tumor	
Lymphocyte	 Ratio	 ITLR,	 Adjacent-to-Tumor	 Lymphocyte	 Ratio	 ATLR	 and	 Distal-To-Tumor	
Lymphocyte	Ratio	DTLR)	and	three	spatial	scores	(Immune	Hotspot,	Cancer	Hotspot,	Immune-
Cancer	Hotspot)	were	calculated	based	on	fully	automated	histology	image	analysis	on	whole	
section	 slides	 (Figure	 2,	 Table	 1,	 Supplementary	 Figure	 2).	 There	 was	 a	 strong,	 negative	
correlation	 between	 ITLR	 and	DTLR	 (r	 =	 -0.888,	Table	 2),	 indicating	 that	 lymphocytes	 either	
infiltrate	 into	close	contact	with	cancer	cells,	or	 largely	stay	 in	the	stromal	area.	Correlations	




correlation	between	 the	pathologist’s	 score	and	all	 automated	 scores	was	 found	 (r	 <	0.260),	





recurrence	 (p	 >	 0.1).	 In	 contrast,	 high	 spatial	 scores	were	 associated	with	 significantly	 poor	
recurrence-free	survival	across	10	years	in	the	univariate	analysis	(n	=	1,178,	Immune	Hotspot	
LR-χ2	 =	 14.06,	 P	 <	 0.001;	 Table	 3).	 When	 dichotomized,	 immune	 spatial	 scores	 were	 also	
prognostic	 (Immune	Hotspot	 training	set	n	=	589,	p	=	0.01,	Hazard	Ratio	HR	=	1.88	and	95%	
Confidence	 Interval	CI	=	 [1.16-3.07];	validation	set	n	=	589,	p	=	0.002,	HR	=	2.21	 [1.35-3.63],	
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Figure	 2,	 Supplementary	 Figure	 4).	 In	 addition,	 immune	 spatial	 scores	 were	 significantly	
prognostic	for	early	(0-5	year)	and	late	recurrence	(5-10	year)	(Immune	Hotspot	0-5	year:	LR-χ2	














RS	 LR-χ2	 =	 7.78,	 Figure	 3).	 None	 of	 these	 scores,	 however,	 added	 to	 IHC4	 and	 RS	 for	 early	
recurrence	(∆LR-χ2	≤	3.84)	or	was	as	prognostic	as	ROR	and	CTS	in	any	time	window	(Figure	3).	
We	 then	examined	 the	additional	prognostic	 value	of	 spatial	 scores	 to	 IHC4	and	RS	 for	0-10	
year	and	late	recurrence.	 Immune-Cancer	Hotspot	provided	statistically	significant	prognostic	
value	 when	 added	 to	 IHC4	 and	 RS	 for	 years	 0-10	 whereas	 Immune	 Hotspot	 also	 added	
prognostic	value	to	IHC4	and	RS	for	late	recurrence	(∆LR-χ2	>	3.84,	Table	4).	Cancer	Hotspot,	on	
the	other	hand,	added	prognostic	information	to	IHC4	and	RS	in	both	time	windows	(Table	4).	
In	 the	 HER2-	 population,	 Immune	 Hotspot	 and	 Immune-Cancer	 Hotspot	 added	 statistically	
significant	 prognostic	 information	 to	 IHC4	 and	 RS	 in	 both	 time	 windows	 (Table	 4).	 Again,	
Cancer	Hotspot	added	statistically	significant	information	to	IHC4	and	RS	in	both	time	windows	
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To	 evaluate	 a	 new	 biomarker	 based	 entirely	 on	 histology	 slides,	 we	 sought	 to	
determine	the	prognostic	value	of	a	combined	model	of	IHC4	and	spatial	scores	for	0-10	year	
and	late	recurrence.	The	prognostic	value	of	IHC4	and	RS	are	similar	in	the	two-time	windows	
and	 populations	 (∆LR-χ2	 ≤	 3.84).	 For	 predicting	 recurrence	 across	 10	 years,	 Cancer	 Hotspot	
combined	 with	 IHC4	 achieved	 a	 better	 performance	 than	 RS	 alone	 in	 both	 cohorts	 (overall	
population	 ∆LR-χ2=	 9.23;	 in	 HER2-:	 ∆LR-χ2	 =	 6.54,	 Figure	 3).	 For	 predicting	 late	 recurrence,	
prognostic	value	higher	than	RS	was	observed	for	IHC4	combined	with	any	of	the	spatial	score	
in	both	populations,	except	 for	 Immune-Cancer	Hotspot	 in	 the	overall	population	 (Figure	 3).	
However,	 none	 of	 the	 combined	 scores	 outperformed	 CTS	 and	 ROR.	 Finally,	 IHC4	 combined	
with	spatial	scores	added	prognostic	value	to	CTS,	similar	to	that	achieved	by	the	RS	but	lower	





In	 this	 study,	 we	 aimed	 to	 establish	 the	 prognostic	 value	 of	 immune	 scores	 for	
recurrence	in	ER+	breast	cancer	patients	treated	with	anastrozole	or	tamoxifen.	While	immune	
response	and	 immunotherapy	 for	ER-	diseases	have	been	under	 the	 spotlight,	 correlation	of	
TILs	with	outcomes	 in	 ER+	disease	 is	 less	 clear	 (16),	with	many	 studies	 reporting	 the	 lack	of	





based	 on	 the	 spatial	 heterogeneity	 of	 TILs	 were	 highly	 prognostic,	 particularly	 for	 late	
recurrence	 after	 5	 years	 of	 endocrine	 therapy.	 This	 suggests	 a	 lasting	 memory	 of	 tumor	
immunity	 on	 disease	 progression	 and	 evolution	 of	 treatment	 resistance	 in	 ER+	 cancer.	 Such	
spatial	heterogeneity	may	reflect	spatial	distribution	patterns	of	different	immune	cell	subsets.	
Intra-tumor	 heterogeneity	 of	 cancer	 cells	 may	 also	 in	 turn	 influence	 immune	 spatial	
distribution	 through	 cytokine	 secretion	 and	 neoantigen	 presentation.	 While	 the	 biological	
mechanisms	 remain	 to	 be	 investigated,	 our	 finding	 has	 significant	 clinical	 implication,	which	
suggests	that	TILs	have	been	previously	overlooked	in	ER+	diseases	due	to	the	lack	of	in-depth	
analysis	of	TILs	on	the	tissue	spatial	organization	level.	Our	findings	highlight	the	importance	of	
examining	not	 just	cell	abundance	but	also	spatial	patterns	that	can	be	 indicative	of	 immune	
functional	phenotypes	and	disease	prognosis.		
In	contrast	to	our	observation	in	ER-	tumors	(13),	high	Immune-Cancer	Hotspot	score,	
indicating	 increased	 spatial	 clustering	 in	 immune	 and	 cancer	 cells,	 correlated	 with	 poor	
prognosis	 in	 ER+	 breast	 cancer.	 However,	 this	 is	 consistent	 with	 our	 previous	 finding	 that	
immune	 gene	 signature	 was	 associated	 with	 poor	 response	 to	 endocrine	 therapy	 in	 a	
neoadjuvant	 setting	 (28,	 29).	 The	 difference	 may	 be	 due	 to	 immune	 composition	 and	
functionality	in	the	two	subtypes,	and	mechanisms	by	which	immune	response	contributes	to	
hormonal	therapy	resistance	(30,	31).	In	a	recent	study	of	immune	composition	in	7,270	breast	
cancers,	higher	 fraction	of	 T-regulatory	 cells	 and	M2	macrophages	and	 lower	 fraction	of	M1	
macrophages	was	found	in	ER+	compared	with	ER-	cancers	(12).	Therefore,	compared	with	ER-	
subtype,	the	immune	landscape	of	ER+	subtype	is	characterized	by	increased	T-cell	regulation	
and	 macrophage	 polarization	 towards	 pro-tumorigenic	 M2,	 which	 is	 consistent	 with	 our	
results.		
Strengths	 of	 this	 study	 include	 the	 large	 patient	 cohort	 with	 long-term	 follow-up	
systematically	 collected	 in	 a	 well-documented	 clinical	 trial,	 well-characterized	 samples	 that	
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enables	 a	 direct	 comparison	 with	 established	 biomarkers,	 and	 fully	 automated	 and	
reproducible	methods	for	immune	scoring.	These	allowed	us	to	evaluate	quantitative	immune	
scoring	 based	 entirely	 on	 H&E-stained	 tumor	 slides,	 which	 are	 readily	 generated	 as	 part	 of	
clinical	 routine.	 Comparison	 of	 the	 automated	 immune	 scores	 with	 a	 pathologist’s	 score	
following	 recommendations	 for	 TIL	 evaluation	 in	 breast	 cancer	 (24)	 in	 a	 subset	 of	 samples	
showed	a	weak	correlation	overall.	This	is,	however,	unsurprising	when	one	considers	that	the	
automated	scores	 include	regions	of	the	tumor	that	are	excluded	on	pathological	evaluation.	
Indeed,	 the	 latter	 includes	 stromal	 TILs	 only,	which	 are	 assessed	 as	percentage	 surface	 area	
that	 is	 inflammatory	as	opposed	to	fibroblastic	 (25).	 In	contrast,	 the	automated	scores	count	
either	the	absolute	number	of	lymphocytes	in	relation	to	cancer	cells,	or	the	frequency	of	(co-
)clustering	 of	 immune	 and	 cancer	 cells.	 Thus,	 the	 information	 gleaned	 from	 these	methods	
potentially	provides	different	biological	 information	about	the	 interaction	between	these	cell	
types,	and,	as	demonstrated	herein,	can	provide	valuable	prognostic	information.	Developing	a	
histology-based	 test	 as	 such	 thus	 has	 the	 advantages	 of	 cost	 effectiveness	 and	 general	
applicability.	 The	prognostic	 value	 of	 immune	 scores	 for	 late	 recurrence	 is	 similar	 to	 that	 of	
IHC4	and	RS	which	is	the	most	widely	used	test	for	residual	risk	of	recurrence	following	surgery	
and	 endocrine.	 Although	 they	 did	 not	 add	 prognostic	 value	 to	 CTS,	 in	 almost	 all	 occasions	




as	 POETIC	 (32).	 In	 addition,	 the	 strong	 prognostic	 value	 of	 CTS	 and	 ROR	 could	 be	 partly	
explained	 by	 the	 use	 of	 tumor	 size	 in	 their	 calculation,	 which	 is	 a	 highly	 prognostic	 factor.	
Furthermore,	 IHC4	 combined	with	 immune	 score	 is	 statistically	 significantly	more	prognostic	




intra-tumor	 heterogeneity	 cannot	 be	 fully	 addressed,	 and	 the	 lack	 of	 immune	markers	 that	
may	provide	further	insights	for	immune	functions	in	ER+	disease	and	better	predictors	due	to	
little	 residual	 tissue	 available.	 In	 addition,	 whether	 our	 methods	 can	 sufficiently	 address	
challenges	 arising	 from	 variability	 in	 factors	 including	 fixation,	 staining,	 and	 acquisition	 in	 a	
clinical	 setting,	 need	 to	 be	 evaluated	 before	 implementation.	 Our	 results	 also	 only	 apply	 to	
women	who	are	chemotherapy-free.	
Furthermore,	our	study	also	provides	relevant	information	for	new	treatment	strategy	
in	 the	 high-risk	 ER+	 population	 identified	 by	 immune	 scores.	 Our	 findings	 support	 different	
immunosuppressive	mechanisms	in	the	ER+	and	ER-subtypes,	and	in	light	of	these	results	call	
for	 the	development	of	novel	 cancer	 therapeutics	 targeting	 the	pathways	 that	 reverse	 these	
mechanisms	specifically	 for	ER+	disease.	This	may	also	help	explain	why	anti-PD1	checkpoint	
inhibition,	 despite	demonstrating	 activity	 as	monotherapy	 in	 early	 phase	 trials	 in	 ER+	breast	
cancer,	 had	 low	 response	 rates	 compared	 with	 triple-negative	 breast	 cancer	 and	 highly	




provided	 an	 additional	 dimension	 to	 the	 analysis	 of	 immune	 functional	 phenotype	 in	 breast	
cancer.	 Spatial	 data	 provided	 by	 histology,	 once	 quantitatively	 analyzed,	 will	 aid	 the	














the	 data;	 the	 writing	 of	 the	 manuscript;	 and	 the	 decision	 to	 submit	 the	 manuscript	 for	
publication.		






















































































































































































































Age	 Grade	 Node	 Size	 Treatment	
TransATAC	 	 	           
ITL	 --	 --	 -- -- -- -- -- -- -- -- -- -- 
ATL	 -0.317	 --	 --	 -- -- -- -- -- -- -- -- -- 
DTL	 -0.888	 -0.154	 --	 --	 -- -- -- -- -- -- -- -- 
LI	 -0.01	 0.381	 -0.174	 --	 --	 -- -- -- -- -- -- -- 
Cancer	Hotspot	 -0.422	 0.309	 0.289	 0.167	 --	 --	 -- -- -- -- -- -- 
Immune	Hotspot	 -0.395	 0.409	 0.213	 0.476	 0.796	 --	 --	 -- -- -- -- -- 
Immune-Cancer	Hotspot	 -0.408	 0.203	 0.327	 0.341	 0.502	 0.75	 --	 --	 -- -- -- -- 
Age	 0.01	 0.018	 -0.019	 -0.036	 0.145	 0.077	 0.033	 --	 --	 -- -- -- 
Grade	 -0.168	 0.126	 0.114	 0.144	 0.268	 0.287	 0.243	 0.128	 --	 --	 -- -- 
node	 0.007	 0.212	 -0.018	 0.213	 0.096	 0.096	 0.107	 0.188	 0.099	 --	 --	 -- 
Size	 0.021	 -0.012	 -0.016	 -0.051	 0.231	 0.194	 0.155	 0.247	 0.171	 0.322	 --	 --	
Treatment	 0.028	 -0.03	 -0.014	 0.044	 -0.023	 0.021	 0.048	 -0.002	 -0.014	 0.007	 0.024	 --	
METABRIC	 	 	 	 	 	 	 	 	 	 	 	 	
ITL	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	
ATL	 -0.276	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	
DTL	 -0.83	 -0.306	 --	 --	 --	 --	 --	 --	 --	 --	 --	 --	
LI	 0.077	 0.199	 -0.191	 --	 --	 --	 --	 --	 --	 --	 --	 --	
Cancer	Hotspot	 -0.331	 0.035	 0.307	 0.062	 --	 --	 --	 --	 --	 --	 --	 --	
Immune	Hotspot	 -0.319	 0.16	 0.223	 0.29	 0.849	 --	 --	 --	 --	 --	 --	 --	
Immune-Cancer	Hotspot	 -0.253	 0.051	 0.221	 0.152	 0.796	 0.824	 --	 --	 --	 --	 --	 --	
*ITLR:	Intra-Tumor	Lymphocyte	Ratio,	ATLR:	Adjacent-to-Tumor	Lymphocyte	Ratio,	DTLRL:	Distal-To-Tumor	Lymphocyte	Ratio,	LI:	Lymphocytic	Infiltration.	
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Table	 3.	 Comparison	of	 prognostic	 value	of	 immune	 scores,	 classical	 clinical	 variables,	 and	



































































































































































































































































































































































HR	(95%CI)	 ∆LR-χ2	 P*	 HR	(95%CI)	 ∆LR-χ2	 P*	
	 	 	 	 	 	 	
Cancer	Hotspot	to	IHC4	 1.22	(1.08-1.37)	 9.72	 0.002	 1.24	(1.04-1.47)	 5.57	 0.02	
Cancer	Hotspot	to	RS	 1.25	(1.11-1.41)	 12.46	 <0.001	 1.27	(1.07-1.49)	 6.97	 0.008	
Immune	Hotspot	to	IHC4	 1.13	(1.01-1.27)	 3.93	 0.05	 1.19	(1.02-1.40)	 4.10	 0.04	
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Immune	Hotspot	to	RS	 1.14	(1.02-1.28)	 4.50	 0.03	 1.21	(1.03-1.42)	 4.71	 0.03	
Immune-Cancer	Hotspot	to	
IHC4	
1.17	(1.04-1.31)	 5.87	 0.02	 NS	 NS	 NS	
Immune-Cancer	Hotspot	to	
RS	
1.15	(1.02-1.29)	 4.76	 0.03	 NS	 NS	 NS	
Her2	subgroup	
0-10	(N=848)	 5-10	(N=733)	
HR	(95%CI)	 ∆LR-χ2	 P*	 HR	(95%CI)	 ∆LR-χ2	 P*	
Cancer	Hotspot	to	IHC4	 1.26	(1.11-1.43)	 11.73	 <0.001	 1.32	(1.12-1.57)	 9.31	 0.002	
Cancer	Hotspot	to	RS	 1.29	(1.14-1.46)	 14.28	 <0.001	 1.37	(1.16-1.61)	 11.82	 <0.001	
Immune	Hotspot	to	IHC4	 1.14	(1.02-1.30)	 4.56	 0.03	 1.23	(1.05-1.44)	 5.71	 0.02	
Immune	Hotspot	to	RS	 1.15	(1.02-1.30)	 4.84	 0.03	 1.26	(1.08-1.47)	 7.12	 0.008	
Immune-Cancer	Hotspot	to	
IHC4	
1.17	(1.04-1.33)	 5.64	 0.02	 1.24	(1.04-1.48)	 4.95	 0.03	
Immune-Cancer	Hotspot	to	
RS	
1.13	(0.99-1.29)	 3.22	 0.07	 1.23	(1.03-1.47)	 4.69	 0.03	





Figure	 1.	 Consort	 diagram	 for	 the	 availability	 of	 samples	 for	 analysis	 from	 the	 ATAC	
(Arimidex,	 Tamoxifen	 Alone	 or	 Combined)	 trial.	 ER,	 estrogen	 receptor;	 IHC,	
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27		
of	TransATAC	H&E	image	and	corresponding	map	of	identified	cancer	and	immune	cells.	Scale	
bar	 illustrates	2.5mm.	B-D)	Visual	 examples	of	hotspots	 and	Kaplan-Meier	 curves	 illustrating	
survival	 associations	 with	 immune	 spatial	 scores.	 Scale	 bar	 illustrates	 35μm.	 Kaplan-Meier	
curves	were	calculated	and	tested	for	equality	using	the	log-rank	test.	The	numbers	of	patients	
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28		
window	in	A)	overall	population	and	B)	HER2-	population.	Kaplan-Meier	curves	were	
calculated	and	tested	for	equality	using	the	log-rank	test.	The	numbers	of	patients	at	risk	in	
each	group	at	various	time	points	are	given	below	each	graph.	All	statistical	tests	were	two-
sided.	
	
	
